Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
Date:8/2/2012

LYNBROOK, N.Y., Aug. 2, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, August 9, 2012 to report its second quarter 2012 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=88477.

A replay of the call will be available one hour after the end of the conference on August 9, 2012 until 9:00 a.m. EDT on August 20, 2012. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10016679. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Today, injectable collagenase, registered as XIAFLEX®, is marketed in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord by the Company's partner Auxilium Pharmaceuticals, Inc. (Auxilium) and is marketed in Europe under the trademark XIAPEX® by Pfizer Ltd. (Pfizer). XIAFLEX is being tested in the clinic for six promising indications during 2012: Auxilium is developing XIAFLEX for the treatment of Peyronie's disease and has announced positive top-line results from two recently completed Phase III clinical trials. Auxilium is also developing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite, which are in Phase IIa and Phase Ib clinical trials, respectively. Auxilium is evaluating XIAFLEX for Dupuytren's contracture patients with multiple palpable cords, for which the Company recently announced positive top-line Phase IIIb clinical trial results. BioSpecifics is also developing XIAFLEX for human and canine lipomas, which are both in Phase II clinical trials. Pfizer has development and commercialization rights for XIAPEX for Dupuytren's contracture and Peyronie's disease in the 27 European Union member countries and 19 other European and Eurasian countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the same two indications in Japan, and Actelion Pharmaceuticals has development and commercialization rights for XIAFLEX for these two indications in Canada, Australia, Brazil and Mexico. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. Life Technologies Announces Second Quarter 2012 Results
3. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
4. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
5. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa
6. Life Technologies Develops Simplified SAME-DAY STEC Solution for Detecting Multiple Strains of E. coli in Ground Beef
7. Ellman International Launches Multi-stage Growth Plan With Acquisition Of Sandstone Medical Technologies
8. Lifeline Biotechnologies First Warning Systems
9. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
10. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics
11. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... June 14, 2017  ivWatch LLC, a medical device ... intravenous (IV) therapy, is pleased to announce it was ... Nonsurgical Hospital Supplies and Equipment at the 2017 Medical ... the medtech industry. The award was presented by Medical ... Javits Center in New York ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/8/2017)... LOS ANGELES , June 8, 2017   Responding ... prescription drug oversight and the death of singer Chris ... Commission on Human Rights International offers a free online ...  to better educate consumers and families about psychotropic drug risks. ... Heath Ledger , who died from an accidental overdose, has ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has ... Dr. Talei has come up with a proprietary technique that he calls the ... that have dropped. For all ages, patients can expect to look refreshed, rejuvenated, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will host ... , The two-day conference is focused on advancing scientific knowledge about the aggressive ... and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” ...
(Date:6/23/2017)... , ... June 23, 2017 , ... MD Now ... This is MD Now’s 28th facility overall and marks the urgent care center's eighth ... one mile North of The Falls shopping mall. The new clinic offers a wide ...
Breaking Medicine News(10 mins):